O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS

O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS

Bibliographic Details
Main Authors:	SMART L., CHARLES M., POWER-HAYS A., HOWARD T., MCELHINNEY K., AMBROSE E., WARE R.
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000872856.73605.c8

Similar Items

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings
by: Luke R. Smart, et al.
Published: (2023-06-01)

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA
by: POWER-HAYS, MD, et al.
Published: (2022-08-01)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
by: Joelma Santana dos Santos Neres, et al.
Published: (2023-06-01)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
by: Galactéros Frédéric, et al.
Published: (2011-05-01)

Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01)

Effect of Concomitant Hydroxyurea Therapy with Rutin and Gallic Acid: Integration of Pharmacokinetic and Pharmacodynamic Approaches
by: Abhishek Gour, et al.
Published: (2021-05-01)

Therapeutic Dose of Hydroxyurea-Induced Synaptic Abnormalities on the Mouse Spermatocyte
by: Xiaobo Fan, et al.
Published: (2021-07-01)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
by: POWER-HAYS A., MD, et al.
Published: (2022-08-01)

Effect of Low Dose of Hydroxyurea in SCD Children with Arab-Indian phenotype- Local Experience
by: Zahra Jaber Hussein
Published: (2023-01-01)

Hydroxyurea utilization and dose optimization in children with sickle cell disease (SCD)
by: Nour Alotaibi, et al.
Published: (2023-01-01)

Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low-dose methotrexate
by: Sarah Mattessich, BS, et al.
Published: (2017-09-01)

Realizing effectiveness across continents with hydroxyurea: enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa
by: McGann, PT, et al.
Published: (2018)

Hydroxyurea-induced melanonychia
by: Michael G. Buontempo, BS, et al.
Published: (2023-12-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Moderate dose of hydroxyurea in children with sickle cell disease and stroke. Preliminary results
by: Sergio Machín-García, et al.

Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository
by: Ju G, et al.
Published: (2024-03-01)

P-047: PROSPECTIVE IDENTIFICATION OF VARIABLES AS OUTCOMES FOR TREATMENT (PIVOT): A PHASE II CLINICAL TRIAL OF HYDROXYUREA FOR CHILDREN AND ADULTS WITH HBSC DISEASE
by: SMART L., et al.
Published: (2022-08-01)

Hydroxyurea—The Good, the Bad and the Ugly
by: Marcelina W. Musiałek, et al.
Published: (2021-07-01)

Hydroxyurea-induced Tooth Discoloration
by: Muhammed Okuyucu, et al.
Published: (2020-02-01)

Blue Lunula Related with Hydroxyurea
by: Hava Üsküdar Teke, et al.
Published: (2013-03-01)

Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study
by: Mohammed Ali Madkhali, et al.
Published: (2024-01-01)

Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations
by: Abdullah Aljutayli, et al.
Published: (2022-04-01)

132:poster Cost-effectiveness of using hydroxyurea to treat sickle cell anemiain uganda: a model-based comparison of two dosing regimens
by: Bjarne Robberstad, et al.
Published: (2022-04-01)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
by: Hui-Yin Yow, et al.
Published: (2022-06-01)

The Role of Hydroxyurea on Growth in Children with SCD
by: Zahrah Mohammed Alkashi
Published: (2023-01-01)

The Use of Hydroxyurea in the Treatment of COVID-19
by: Foster Melissa Robin Bowman, et al.
Published: (2021-10-01)

Oral lesions associated with hydroxyurea treatment
by: Regina Mendonça, et al.
Published: (2011-01-01)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
by: Luiz Bernardino Lima da Silva, et al.
Published: (2012-01-01)

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
by: Emily R. Meier, et al.
Published: (2020-11-01)

Hydroxyurea and sickle cell anemia: effect on quality of life
by: Pegelow Charles H, et al.
Published: (2006-08-01)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
by: Nan Yang, et al.
Published: (2022-05-01)

Role of Hydroxyurea in Patients of Beta Thalassemia Majo
by: Benish Fatima, et al.
Published: (2022-12-01)

Phases of crown-gall transformation susceptible to hydroxyurea
by: Aldona Rennert, et al.
Published: (2014-01-01)

Leg ulcer with long‐term hydroxyurea use
by: Mohammad Ammad Ud Din, et al.
Published: (2021-04-01)

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
by: Lebensburger JD, et al.
Published: (2015-12-01)

Tratamiento con dosis moderada de hidroxiurea en la drepanocitosis Treatment with moderate doses of hydroxyurea in drepanocytosis
by: Sergio Machín García, et al.
Published: (2008-08-01)

Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing
by: Efthymios Neroutsos, et al.
Published: (2022-03-01)